Nearly half ofthe 20 designs achieved >100-fold affinity reduction, with themosteffective mask decreasing EGFR binding by over 3 orders of magnitude.Upon cleavage by tumor-associated proteases, binding was restoredin 19 out of 20 cases, confirming reversibility. The gene discussed is EGFR; the disease is neoplasm.